Pulmonary Drugs - Global Market Insights, Competitive Landscape, and Market Forecast - 2028

Pulmonary Drugs Market By Drug Class (Beta-2 Agonists, Corticosteroids, Anticholinergic Agents, Antihistamines, And Others), Indication (Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Cystic Fibrosis, Chronic Bronchitis, And Others), Distribution Channel (Hospital And Retail Pharmacies, E-Commerce, And Others) and geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of pulmonary disorders and augmented levels of air pollution globally during the forecast period from 2023-2028.

The demand for pulmonary drugs is primarily being boosted owing to the rising prevalence of pulmonary disorders, the augmented levels of air pollution globally, the increasing awareness amongst patients in the management of asthma and COPD, among others, during the forecast period from 2023-2028.

Pulmonary Drugs Market Dynamics:

In the global Pulmonary Drugs market, the estimated high numbers of pulmonary diseases are expected to drive the demand for Pulmonary Drugs in the upcoming years. For example, according to the World Health Organization (WHO) 2022, it was estimated in 2019 that worldwide around 262 million people were suffering from asthma in 2019.

Also, as per the WHO data on Chronic Obstructive pulmonary disorder 2022, globally around 3.23 million deaths had occurred owing to the COPD disorder in the year 2019. As per the aforementioned source, about 90% of the COPD deaths had occurred in low- and middle-income countries, amongst the patients under the age of 70 years.

As per the Asthma and Allergy Foundation of America 2022, approximately 25 million people in the United States were suffering from asthma in the year 2020. The same source had also stated that in 2020, about 20 million United States adults aged 18 and above were suffering from asthma.

The Asthma and Lung UK Organization 2022, had also stated that in UK, about 5.4 million people suffer from asthma disorder in 2021. The number accounts to about one in every 12 adults and one in every 11 children.

The Australian Bureau of Statistics 2022, also revealed there numbers suggesting that under 2.7 million (10.7%) Australian patients were suffering from asthma in 2020-21.

The Interactive Health Atlas of Lung conditions in England (INHALE) 2022 revealed that in UK, the emergency hospital admissions for COPD patients was observed to be 133.5 per 100,000 population in the financial year ending 2021.

The above-mentioned facts illustrate the rising prevalence of pulmonary disorders across the globe, which will lead to an increase in the demand for pulmonary drugs for their treatment and management in the upcoming years.

Hence, the interplay of all the above-mentioned factors is anticipated to increase the overall market growth for Pulmonary Drugs during the forecast period from 2023 - 2028.

However, the availability of alternate routes of treatment administration, and various side effects associated with drugs, among others may restrict the growth of the overall market for Pulmonary Drugs during the forecast period.

Pulmonary Drugs Market Segment Analysis:

Pulmonary Drugs Market By Drug Class (Beta-2 Agonists, Corticosteroids, Anticholinergic Agents, Antihistamines, And Others), Indication (Asthma, Chronic Obstructive Pulmonary Disorder (COPD), Cystic Fibrosis, Chronic Bronchitis, And Others), Distribution Channel (Hospital And Retail Pharmacies, E-Commerce, And Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the indication segment of the Pulmonary Drugs market, the Chronic Obstructive Pulmonary Disorder (COPD) category is expected to amass a significant revenue share in the year 2022. This can be ascribed to the growing prevalence of COPD globally, the growing population of smokers, and the increasing number of drug launches for COPD, which is expected to propel the overall market during the forecast period.

As per data by the Global Burden of Disease Study (2019), there were 212.3 million prevalent cases of COPD reported globally, accounting for 3.3 million deaths in the year 2019. Furthermore, as per data by the Institute for Health Research and Policy (2022), reported that there were 1.1 billion smokers present worldwide and 200 million more who used other tobacco products, in the year 2022. Due to an increase in the number of smoking population globally, the figures for the number of people getting affected by COPD is also increasing, leading to increased demand for pulmonary drugs.

Moreover, the rising drug launches and approvals of COPD-based pulmonary drugs is also expected to boost the market demand for pulmonary drugs during the forecast period.

For example, in November 2023, Lupin announced the launch of Vilfuro-G in India, the world's first fixed-dose triple combination drug for the effective management of chronic obstructive pulmonary disease (COPD) in India. Lupin's Vilfuro-G is the sole FDC that combines Vilanterol, Fluticasone Furoate, and Glycopyrronium Bromide, catering to the long-term management and treatment of moderate to severe COPD.

Therefore, the increasing number of COPD affected patients coupled with the recent drug launches in the COPD segment for pulmonary drugs present a positive outlook among other indications in the Pulmonary Drugs market.

North America is expected to dominate the overall Pulmonary Drugs Market:

Among all the regions, North America is estimated to account for the largest share of the Pulmonary Drugs market in the year 2022. Owing to the surging prevalence of asthma, chronic obstructive pulmonary disorder (COPD), and others, increasing exposure to smoke, dust, fumes, chemicals, and others, and the growing product development activities in the pulmonary drugs sector among others in North America, it is expected to propel the overall market growth during the forecast period from 2023-2028.

As per the data published by World Health Organization (WHO) 2021, approximately 25 million people in the United States had asthma in the year 2020, including 4.2 million children. This equals about 1 in every 13 people.

The National Center for Health Statistics 2019-2020, stated that the percentage of COPD, emphysema, or chronic bronchitis for adults aged 18 and over, in the United States, increased from 4.6% in 2019 to 5.0% in 2020.

The increasing number of product development activities in the region is further going to accelerate the growth of the Pulmonary Drugs market. For example, in January 2023, the US Food and Drug Administration approved Airsupra for adults with asthma. The drug became the first approved to combine albuterol (a beta-2 adrenergic agonist) and budesonide (a corticosteroid).

Considering the presence of a large patient pool in the US coupled with new product approvals, the market for pulmonary drugs looks promising in North America.

Hence, all the above stated factors are likely to boost the Pulmonary Drugs market in North America during the forecast period (2023-2028).

Pulmonary Drugs Market Key Players:

Some of the key market players operating in the Pulmonary Drugs market include F. Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline plc., Sanofi, Grifols S.A., Regeneron Pharmaceuticals, Circassia Pharmaceuticals Plc, Pfizer Inc., Teva Pharmaceutical Industries, Sumitomo Dainippon Pharma Co., Ltd., Merck & Co., Inc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., VAPOTHERM, Cardinal Health, NSPIRE Health Inc., Allied Healthcare, Lupin Ltd., and others.

Recent Developmental Activities in the Pulmonary Drugs Market:

• In July 2023, Viatris announced launch of breyna™ (budesonide and formoterol fumarate dihydrate) inhalation aerosol, the first FDA-approved generic version of symbicort® for people with asthma and chronic obstructive pulmonary disease, in partnership with Kindeva.
• In July 2023, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
• In May 2023, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the prevention of lower respiratory tract disease caused by RSV in individuals 60 years of age and older.

Key Takeaways from the Pulmonary Drugs Market Report Study

• Market size analysis for current Pulmonary Drugs market size (2022), and market forecast for 5 years (2023-2028)
• Top key research and clinical developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Pulmonary Drugs market.
• Various opportunities available for other competitors in the Pulmonary Drugs market space.
• What are the top-performing segments in 2022? How these segments will perform in 2028?
• Which are the top-performing regions and countries in the current Pulmonary Drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Pulmonary Drugs market growth in the coming future?

Target Audience who can benefit from this Pulmonary Drugs Market Report Study

• Pulmonary Drug product providers
• Research organizations and consulting companies
• Pulmonary Drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Pulmonary Drugs
• Various end-users who want to know more about pulmonary disorders and its related treatment and management market, along with the latest research developments in the Pulmonary Drugs market.

Frequently Asked Questions for the Pulmonary Drugs Market:

1. What are Pulmonary Drugs?
Pulmonary Drugs are the drugs that are prescribed for the treatment and management of pulmonary and respiratory conditions such as asthma, COPD, and bronchitis, among others.

2. What are the drivers for the global Pulmonary Drugs market?
The demand for pulmonary drugs is primarily being boosted owing to the rising prevalence of pulmonary disorders, the augmented levels of air pollution globally, and the increasing awareness amongst patients in the management of asthma and COPD, among others, during the forecast period from 2023-2028.

3. Who are the key players operating in the global Pulmonary Drugs market?
Some of the key market players operating in the Pulmonary Drugs market include F. Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline plc., Sanofi, Grifols S.A., Regeneron Pharmaceuticals, Circassia Pharmaceuticals Plc, Pfizer Inc., Teva Pharmaceutical Industries, Sumitomo Dainippon Pharma Co., Ltd., Merck & Co., Inc., Mallinckrodt Pharmaceuticals Plc., Cheisi farmaceutici S.p.A., Zambon Company S.p.A., VAPOTHERM, Cardinal Health, NSPIRE Health Inc., Allied Healthcare, Lupin Ltd.

4. Which region has the highest share in the Pulmonary Drugs market?
North America is expected to dominate the overall Pulmonary Drugs market during the forecast period from 2023-2028. Owing to the surging prevalence of asthma, chronic obstructive pulmonary disorder (COPD), and others, increasing exposure to smoke, dust, fumes, chemicals, and others, and the growing product development activities in the pulmonary drugs sector among others in North America, it is expected to propel the overall market growth during the forecast period from 2023-2028.


This product will be delivered within 3-5 business days.